Texas Bank & Trust Co Acquires Shares of 2,100 Zoetis Inc. (NYSE:ZTS)

Texas Bank & Trust Co acquired a new stake in Zoetis Inc. (NYSE:ZTS) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 2,100 shares of the company’s stock, valued at approximately $342,000.

A number of other large investors have also recently made changes to their positions in the business. Tidal Investments LLC lifted its stake in shares of Zoetis by 22.7% in the fourth quarter. Tidal Investments LLC now owns 18,668 shares of the company’s stock valued at $3,042,000 after buying an additional 3,458 shares in the last quarter. State of Wyoming lifted its stake in shares of Zoetis by 1,074.0% in the fourth quarter. State of Wyoming now owns 2,125 shares of the company’s stock valued at $346,000 after buying an additional 1,944 shares in the last quarter. Strategic Wealth Partners Ltd. lifted its stake in shares of Zoetis by 20.1% in the fourth quarter. Strategic Wealth Partners Ltd. now owns 48,024 shares of the company’s stock valued at $7,922,000 after buying an additional 8,052 shares in the last quarter. Strive Asset Management LLC bought a new position in shares of Zoetis in the fourth quarter valued at $501,000. Finally, Toronto Dominion Bank lifted its stake in shares of Zoetis by 4.3% in the fourth quarter. Toronto Dominion Bank now owns 243,573 shares of the company’s stock valued at $39,684,000 after buying an additional 10,087 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Stock Performance

Shares of ZTS stock opened at $163.03 on Monday. The firm has a market cap of $72.58 billion, a price-to-earnings ratio of 29.80, a P/E/G ratio of 2.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. Zoetis Inc. has a 52 week low of $139.70 and a 52 week high of $200.33. The firm’s 50-day simple moving average is $156.46 and its two-hundred day simple moving average is $165.22.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.40 by $0.08. The business had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.20 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The company’s revenue for the quarter was up 1.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.38 earnings per share. As a group, equities analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Insider Transactions at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the sale, the executive vice president now directly owns 15,781 shares in the company, valued at approximately $2,682,770. This represents a 2.02% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the transaction, the director now owns 11,245 shares of the company’s stock, valued at $1,868,244.30. This represents a 9.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.18% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ZTS. Morgan Stanley dropped their price target on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. Barclays raised their price target on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. StockNews.com raised shares of Zoetis from a “hold” rating to a “buy” rating in a research report on Friday, March 7th. UBS Group dropped their price target on shares of Zoetis from $189.00 to $170.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 7th. Finally, Piper Sandler raised their price target on shares of Zoetis from $205.00 to $210.00 and gave the company an “overweight” rating in a research report on Monday, May 12th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Zoetis has a consensus rating of “Buy” and an average price target of $212.75.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.